There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Inspection Record
ADMA Biologics, Inc — FDA 483 Findings
Inspectors Thai D Truong · Burnell M Henry · Jennifer L ReedThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- SciVac LTD2023-03-27 · US FDASimilar to finding 2 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
- Serum Institute of India Pvt. Ltd.2022-04-19 · US FDASimilar to finding 3 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
- OPS International Inc dba Olympia Pharmaceuticals2026-09-03 · US FDASimilar to finding 3 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
- MSD Ireland (Carlow)2025-04-01 · US FDASimilar to finding 3 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
- GlaxoSmithKline Biologicals2024-03-12 · US FDASimilar to finding 1 There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.